Drug Trial Radar · NCT05599789
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
47
Planned (sponsor's estimate)
Start
Feb 1, 2023
Primary completion
May 21, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Peking Union Medical College HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BeyondSpring Pharmaceuticals Inc.; Merck Sharp & Dohme LLC
- First posted
- Oct 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet Chemotherapy.
Conditions
- Non Small Cell Lung Cancer Metastatic
Interventions
Pembrolizumab in Combination with Plinabulin and DocetaxelDrug
Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR, objective response rateTime frame: through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.